A publication of the Kentucky Center for Public Service Journalism

Bexion Pharmaceuticals, Inc. announces data from ongoing Phase I BXQ-350 clinical trial

 Covington-based Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of its ongoing Phase I Safety Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting Poster Session, held in Chicago June 1-5.

In the poster presentation entitled, “First-in-class Phase Ia Study of BXQ-350 for Solid Tumors and Gliomas”, the preliminary data showed:

*9 patients with Glioblastoma Multiforme (GBM); 8 patients with other solid tumors

*Patients had a median 7 prior systemic therapies

*No Dose Limiting Toxicities (DLTs)

*No treatment –related serious adverse events (SAEs)

*Most common treatment-related moderate AEs were transient fatigue

*Best response in 7 patients completing to day 113:

– 1 Partial Response (appendiceal carcinoma)
– Stable Disease (improved day 113 RANO/RECIST)

*1 High Grade Glioma Stable Disease >19+ months

Dr. Takigiku

“Bexion’s team was excited to share our Phase Ia data at the ASCO conference,” stated Dr. Ray Takigiku, founder and CEO. “With this promising data indicating the potential for a tumor agnostic approach, Bexion is now enrolling patients with solid tumors and gliomas in Phase 1b, and we are initiating efforts to towards a Phase 1 trial in pediatrics and combination Phase 2 studies in adults.”

BXQ-350 is a unique formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS).  

Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer. Bexion’s first-in-class biologic, BXQ-350, has demonstrated selective tumor targeting with the potential for clinical efficacy in a broad range of cancers.

In 2013 the NCI awarded Bexion a prestigious “Bridge Award” of $3MM to support testing of BXQ-350 in the clinic. In February 2015, the FDA granted Bexion Orphan Drug status for Saposin C, the active ingredient in its proprietary drug BXQ-350, for the potential treatment of glioblastoma multiforme (GBM), a type of brain cancer.

In June 2015, Bexion won a Tibbett’s Award by the Small Business Administration for exemplifying the very best in innovation. Currently Bexion is in a Series B Fund Raise. For more information, click here.

Bexion Pharmaceuticals

Related Posts

Leave a Comment